Apathy in patients with Parkinson’s disease following deep brain stimulation of the subthalamic nucleus

Research output: Contribution to journalSpecial issuepeer-review

Standard

Apathy in patients with Parkinson’s disease following deep brain stimulation of the subthalamic nucleus. / Hindle Fisher, Isabel; Pall, Hardev; Mitchell, Rosalind D; Kausar, Jamilia; Cavanna, Andrea E.

In: CNS spectrums, Vol. 21, No. 3, 06.05.2016, p. 258-264.

Research output: Contribution to journalSpecial issuepeer-review

Harvard

APA

Vancouver

Author

Hindle Fisher, Isabel ; Pall, Hardev ; Mitchell, Rosalind D ; Kausar, Jamilia ; Cavanna, Andrea E. / Apathy in patients with Parkinson’s disease following deep brain stimulation of the subthalamic nucleus. In: CNS spectrums. 2016 ; Vol. 21, No. 3. pp. 258-264.

Bibtex

@article{be6b517725c34edd91625c4f698a807e,
title = "Apathy in patients with Parkinson{\textquoteright}s disease following deep brain stimulation of the subthalamic nucleus",
abstract = "Apathy has been reported as a possible adverse effect of deep brain stimulation of the subthalamic nucleus (STN-DBS). We investigated the prevalence and severity of apathy in 22 patients with Parkinson{\textquoteright}s disease (PD) who underwent STN-DBS, as well as the effects of apathy on quality of life (QOL). All patients were assessed with the Lille Apathy Rating Scale (LARS), the Apathy Scale (AS), and the Parkinson{\textquoteright}s Disease Questionnaire and were compared to a control group of 38 patients on pharmacotherapy alone. There were no significant differences in the prevalence or severity of apathy between patients who had undergone STN-DBS and those on pharmacotherapy alone. Significant correlations were observed between poorer QOL and degree of apathy, as measured by the LARS (p<0.001) and the AS (p=0.021). PD-related disability also correlated with both apathy ratings (p<0.001 and p=0.017, respectively). Our findings suggest that STN-DBS is not necessarily associated with apathy in the PD population; however, more severe apathy appears to be associated with a higher level of disability due to PD and worse QOL, but no other clinico-demographic characteristics.",
author = "{Hindle Fisher}, Isabel and Hardev Pall and Mitchell, {Rosalind D} and Jamilia Kausar and Cavanna, {Andrea E}",
year = "2016",
month = may,
day = "6",
doi = "10.1017/S1092852916000171",
language = "English",
volume = "21",
pages = "258--264",
journal = "CNS spectrums",
issn = "1092-8529",
publisher = "Cambridge University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Apathy in patients with Parkinson’s disease following deep brain stimulation of the subthalamic nucleus

AU - Hindle Fisher, Isabel

AU - Pall, Hardev

AU - Mitchell, Rosalind D

AU - Kausar, Jamilia

AU - Cavanna, Andrea E

PY - 2016/5/6

Y1 - 2016/5/6

N2 - Apathy has been reported as a possible adverse effect of deep brain stimulation of the subthalamic nucleus (STN-DBS). We investigated the prevalence and severity of apathy in 22 patients with Parkinson’s disease (PD) who underwent STN-DBS, as well as the effects of apathy on quality of life (QOL). All patients were assessed with the Lille Apathy Rating Scale (LARS), the Apathy Scale (AS), and the Parkinson’s Disease Questionnaire and were compared to a control group of 38 patients on pharmacotherapy alone. There were no significant differences in the prevalence or severity of apathy between patients who had undergone STN-DBS and those on pharmacotherapy alone. Significant correlations were observed between poorer QOL and degree of apathy, as measured by the LARS (p<0.001) and the AS (p=0.021). PD-related disability also correlated with both apathy ratings (p<0.001 and p=0.017, respectively). Our findings suggest that STN-DBS is not necessarily associated with apathy in the PD population; however, more severe apathy appears to be associated with a higher level of disability due to PD and worse QOL, but no other clinico-demographic characteristics.

AB - Apathy has been reported as a possible adverse effect of deep brain stimulation of the subthalamic nucleus (STN-DBS). We investigated the prevalence and severity of apathy in 22 patients with Parkinson’s disease (PD) who underwent STN-DBS, as well as the effects of apathy on quality of life (QOL). All patients were assessed with the Lille Apathy Rating Scale (LARS), the Apathy Scale (AS), and the Parkinson’s Disease Questionnaire and were compared to a control group of 38 patients on pharmacotherapy alone. There were no significant differences in the prevalence or severity of apathy between patients who had undergone STN-DBS and those on pharmacotherapy alone. Significant correlations were observed between poorer QOL and degree of apathy, as measured by the LARS (p<0.001) and the AS (p=0.021). PD-related disability also correlated with both apathy ratings (p<0.001 and p=0.017, respectively). Our findings suggest that STN-DBS is not necessarily associated with apathy in the PD population; however, more severe apathy appears to be associated with a higher level of disability due to PD and worse QOL, but no other clinico-demographic characteristics.

U2 - 10.1017/S1092852916000171

DO - 10.1017/S1092852916000171

M3 - Special issue

VL - 21

SP - 258

EP - 264

JO - CNS spectrums

JF - CNS spectrums

SN - 1092-8529

IS - 3

ER -